What the infectious disease physician needs to know about pegylated interferon and ribavirin.
Clin Infect Dis
; 56(11): 1629-36, 2013 Jun.
Article
en En
| MEDLINE
| ID: mdl-23429551
ABSTRACT
The treatment of chronic hepatitis C is rapidly evolving from triple therapy to regimens that do not require interferon or even ribavirin. However, pegylated interferon and ribavirin will remain the backbone of hepatitis C therapy for the time being. This review summarizes the pharmacokinetics of peginterferon and ribavirin with a particular emphasis on their side-effect profile and management. Finally, the continued role of peginterferon and ribavirin in future therapies will be discussed.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Polietilenglicoles
/
Ribavirina
/
Interferones
/
Hepatitis C Crónica
Límite:
Humans
Idioma:
En
Revista:
Clin Infect Dis
Asunto de la revista:
DOENCAS TRANSMISSIVEIS
Año:
2013
Tipo del documento:
Article
País de afiliación:
Estados Unidos